Therapies for coronaviruses. Part 2: inhibitors of intracellular life cycle

Bibliography

• Cavanagh D. Nidovirales: a new order comprising Coronaviridae and Arteriviridae. Arch virol 1997;142(3):629-33
   PubMed Web of Science ®Google Scholar
• Tong TR. In: Tabor E, editor, Emerging viruses in human populations: Elsevier; 2007; p. 43-96
   Google Scholar
• Thiel V, Ivanov KA, Putics A, et al. Mechanisms and enzymes involved in SARS coronavirus genome expression. J Gen Virol 2003;84(Pt 9):2305-15
   PubMed Web of Science ®Google Scholar
• Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science (New York) 2003;300(5626):1763-7
   Google Scholar
• Fan K, Wei P, Feng Q, et al. Biosynthesis, purification, and substrate specificity of severe acute respiratory syndrome coronavirus 3C-like proteinase. J Biol Chem 2004;279(3):1637-42
   PubMed Web of Science ®Google Scholar
• Yang S, Chen SJ, Hsu MF, et al. Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. J Med Chem 2006;49(16):4971-80
   PubMed Web of Science ®Google Scholar
• Ivanov KA, Thiel V, Dobbe JC, et al. Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase. J Virol 2004;78(11):5619-32
   PubMed Web of Science ®Google Scholar
• Snijder EJ, Bredenbeek PJ, Dobbe JC, et al. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol 2003;331(5):991-1004
   PubMed Web of Science ®Google Scholar
• Prentice E, McAuliffe J, Lu X, et al. Identification and characterization of severe acute respiratory syndrome coronavirus replicase proteins. J Virol 2004;78(18):9977-86
   PubMed Web of Science ®Google Scholar
• Van Hemert MJ, Van Den Worm SH, Knoops K, et al. SARS-coronavirus replication/transcription complexes are membrane-protected and need a host factor for activity in vitro. PLoS Pathog 2008;4(5):e1000054
   PubMed Web of Science ®Google Scholar
• Tanner JA, Watt RM, Chai YB, et al. The severe acute respiratory syndrome (SARS) coronavirus NTPase/helicase belongs to a distinct class of 5′ to 3′ viral helicases. J Biol Chem 2003;278(41):39578-82
   PubMed Web of Science ®Google Scholar
• Haasnoot J, Westerhout EM, Berkhout B. RNA interference against viruses: strike and counterstrike. Nat Biotechnol 2007;25(12):1435-43
   PubMed Web of Science ®Google Scholar
• Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001;14(4):778-809
   PubMed Web of Science ®Google Scholar
• Mohapatra SS, Behera AK, inventors; University of South Florida, Tampa, FL (US), assignee. Materials and methods for prevention and treatment of RNA viral diseases. Patent US7354908; 2008
   Google Scholar
• Bass BL. RNA editing by adenosine deaminases that act on RNA. Annu Rev Biochem 2002;71:817-46
   PubMed Web of Science ®Google Scholar
• Bishop KN, Holmes RK, Sheehy AM, Malim MH. APOBEC-mediated editing of viral RNA. Science (New York) 2004;305(5684):645
   Google Scholar
• Ip WK, Chan KH, Law HK, et al. Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. J Infect Dis 2005;191(10):1697-704
   PubMed Web of Science ®Google Scholar
• Lau YL, Peiris JM. Pathogenesis of severe acute respiratory syndrome. Curr Opin Immunol 2005;17(4):404-10
   PubMedGoogle Scholar
• Sui J, Li W, Murakami A, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci USA 2004;101(8):2536-41
   PubMed Web of Science ®Google Scholar
• Sui J, Li W, Roberts A, et al. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol 2005;79(10):5900-6
   PubMed Web of Science ®Google Scholar
• Pyrc K, Bosch BJ, Berkhout B, et al. Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob Agents Chemother 2006;50(6):2000-8
   PubMed Web of Science ®Google Scholar
• Bacha U, Barrila J, Velazquez-Campoy A, et al. Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro. Biochemistry 2004;43(17):4906-12
   PubMed Web of Science ®Google Scholar
• Lee TW, Cherney MM, Huitema C, et al. Crystal Structures of the Main Peptidase from the SARS Coronavirus Inhibited by a Substrate-like Aza-peptide Epoxide. J Mol Biol 2005;353(5):1137-51
   PubMed Web of Science ®Google Scholar
• Martina E, Stiefl N, Degel B, et al. Screening of electrophilic compounds yields an aziridinyl peptide as new active-site directed SARS-CoV main protease inhibitor. Bioorg Med Chem Lett 2005;15(24):5365-9
   PubMed Web of Science ®Google Scholar
• Jain RP, Pettersson HI, Zhang J, et al. Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro. J Med Chem 2004;47(25):6113-6
   PubMed Web of Science ®Google Scholar
• Shie JJ, Fang JM, Kuo CJ, et al. Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease. J Med Chem 2005;48(13):4469-73
   PubMed Web of Science ®Google Scholar
• Blanchard JE, Elowe NH, Huitema C, et al. High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase. Chem Biol 2004;11(10):1445-53
   PubMed Web of Science ®Google Scholar
• Lau SK, Woo PC, Li KS, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proc Natl Acad Sci USA 2005;102(39):14040-5
   PubMed Web of Science ®Google Scholar
• Li W, Shi Z, Yu M, et al. Bats Are Natural Reservoirs of SARS-Like Coronaviruses. Science 2005;310(5748):676-9
   PubMed Web of Science ®Google Scholar
• Grum-Tokars V, Ratia K, Begaye A, et al. Evaluating the 3C-like protease activity of SARS-Coronavirus: recommendations for standardized assays for drug discovery. Virus Res 2008;133(1):63-73
   PubMed Web of Science ®Google Scholar
• Pang YP. Three-dimensional model of a substrate-bound SARS chymotrypsin-like cysteine proteinase predicted by multiple molecular dynamics simulations: catalytic efficiency regulated by substrate binding. Proteins 2004;57(4):747-57
   PubMedGoogle Scholar
• Shi J, Wei Z, Song J. Dissection study on the severe acute respiratory syndrome 3C-like protease reveals the critical role of the extra domain in dimerization of the enzyme: defining the extra domain as a new target for design of highly specific protease inhibitors. J Biol Chem 2004;279(23):24765-73
   PubMedGoogle Scholar
• Yang H, Xie W, Xue X, et al. Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases. PLoS Biol 2005;3(10):e324
   PubMed Web of Science ®Google Scholar
• Xue X, Yu H, Yang H, et al. Structures of two coronavirus main proteases: implications for substrate binding and antiviral drug design. J Virol 2008;82(5):2515-27
   PubMed Web of Science ®Google Scholar
• Zhao Q, Li S, Xue F, et al. Structure of the Main Protease from a Global Infectious Human Coronavirus, HCoV-HKU1. J Virol 2008;82(17):8647-55
   PubMed Web of Science ®Google Scholar
• Dooley AJ, Shindo N, Taggart B, et al. From genome to drug lead: identification of a small-molecule inhibitor of the SARS virus. Bioorg Med Chem Lett 2006;16(4):830-3
   PubMedGoogle Scholar
• Liu Z, Huang C, Fan K, et al. Virtual screening of novel noncovalent inhibitors for SARS-CoV 3C-like proteinase. J Chem Inf Model 2005;45(1):10-7
   PubMedGoogle Scholar
• Pang YP, Dooley AJ, Park JG, inventors; Antiviral compositions and methods. Patent US20070149487; 2007
   Google Scholar
• Shen J, Jiang H, Shen X, et al., inventors; 3D-structure model of SARS coronavirus 3CL protease and anti-SARS drugs. Patent US20060142383; 2006
   Google Scholar
• Rubin B, Piala JJ, Burke JC, Craver BN. A New, Potent and Specific Serotonin Inhibitor, (Sq 10,643) 2′-(3-Dimethylaminopropylthio) Cinnamanilide Hydrochloride: Antiserotonin Activity on Uterus and on Gastrointestinal, Vascular, and Respiratory Systems of Animals. Arch Int Pharmacodynamie Ther 1964;152:132-43
   PubMedGoogle Scholar
• Itil TM, Polvan N, Holden JM. Clinical and electroencephalographic effects of cinanserin in schizophrenic and manic patients. Dis Nerv Syst 1971;32(3):193-200
   PubMedGoogle Scholar
• Chen L, Gui C, Luo X, et al. Cinanserin is an inhibitor of the 3C-like proteinase of severe acute respiratory syndrome coronavirus and strongly reduces virus replication in vitro J Virol 2005;79(11):7095-103
   PubMed Web of Science ®Google Scholar
• Hertzig T, Scandella E, Schelle B, et al. Rapid identification of coronavirus replicase inhibitors using a selectable replicon RNA. J Gen Virol 2004;85(Pt 6):1717-25
   PubMedGoogle Scholar
• Wong CH, Wu CY, Tan JT, inventors; Anti-coronavirus compounds. Patent US20060160866; 2006
   Google Scholar
• Wu CY, Jan JT, Ma SH, et al. Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci USA 2004;101(27):10012-7
   PubMed Web of Science ®Google Scholar
• Wu SY, Hsieh HP, Hsu TA, inventors; SARS CoV main protease inhibitors. Patent US20060019967; 2006
   Google Scholar
• Yang S, Wu JD, Su FY, et al., inventors; Protease inhibitors. Patent 20050143320; 2005
   Google Scholar
• Barrila J, Bacha U, Freire E. Long-range cooperative interactions modulate dimerization in SARS 3CLpro. Biochemistry 2006;45(50):14908-16
   PubMedGoogle Scholar
• Freire E, Ottenbrite R, Xiao Y, et al., inventors; Inhibitors of coronavirus protease and methods of use thereof. Patent US20050267071; 2005
   Google Scholar
• Ratia K, Saikatendu KS, Santarsiero BD, et al. Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme. Proc Natl Acad Sci USA 2006;103(15):5717-22
   PubMed Web of Science ®Google Scholar
• Lindner HA, Fotouhi-Ardakani N, Lytvyn V, et al. The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme. J Virol 2005;79(24):15199-208
   PubMed Web of Science ®Google Scholar
• Barretto N, Jukneliene D, Ratia K, et al. The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. J Virol 2005;79(24):15189-98
   PubMed Web of Science ®Google Scholar
• Sulea T, Lindner HA, Purisima EO, Menard R. Deubiquitination, a new function of the severe acute respiratory syndrome coronavirus papain-like protease? J Virol 2005;79(7):4550-1
   PubMed Web of Science ®Google Scholar
• Devaraj SG, Wang N, Chen Z, et al. Regulation of IRF-3-dependent innate immunity by the papain-like protease domain of the severe acute respiratory syndrome coronavirus. J Biol Chem 2007;282(44):32208-21
   PubMed Web of Science ®Google Scholar
• Spiegel M, Pichlmair A, Martinez-Sobrido L, et al. Inhibition of Beta interferon induction by severe acute respiratory syndrome coronavirus suggests a two-step model for activation of interferon regulatory factor 3. J Virol 2005;79(4):2079-86
   PubMed Web of Science ®Google Scholar
• Ratia K, Pegan S, Takayama J, et al. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc Natl Acad Sci USA 2008;105(42):16119-24
   PubMed Web of Science ®Google Scholar
• Chen XP, Li GH, Tang XP, et al. Lack of severe acute respiratory syndrome in 19 AIDS patients hospitalized together. J Acquir Immune Defic Syndr 2003;34(2):242-3
   PubMedGoogle Scholar
• Chen XP, Cao Y. Consideration of highly active antiretroviral therapy in the prevention and treatment of severe acute respiratory syndrome. Clin Infect Dis 2004;38(7):1030-2
   PubMedGoogle Scholar
• Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J 2003;9(6):399-406
   PubMedGoogle Scholar
• Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59(3):252-6
   PubMed Web of Science ®Google Scholar
• Zhang XW, Yap YL. Old drugs as lead compounds for a new disease? Binding analysis of SARS coronavirus main proteinase with HIV, psychotic and parasite drugs. Bioorg Med Chem 2004;12(10):2517-21
   PubMed Web of Science ®Google Scholar
• Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 2004;31(1):69-75
   PubMed Web of Science ®Google Scholar
• Yamamoto N, Yang R, Yoshinaka Y, et al. HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus. Biochem Biophys Res Commun 2004;318(3):719-25
   PubMed Web of Science ®Google Scholar
• Hsu JT, Kuo CJ, Hsieh HP, et al. Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV. FEBS Lett 2004;574(1-3):116-20
   PubMed Web of Science ®Google Scholar
• Liu YC, Huang V, Chao TC, et al. Screening of drugs by FRET analysis identifies inhibitors of SARS-CoV 3CL protease. Biochem Biophys Res Commun 2005;333(1):194-9
   PubMed Web of Science ®Google Scholar
• Barnard DL, Day CW, Bailey K, et al. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir Chem Chemother 2006;17(5):275-84
   PubMedGoogle Scholar
• Fujii N, Yamamoto N, inventors; Arigen, Inc., Tokyo (JP), assignee. Anti-coronavirus drug patent 20060223847; 2006
   Google Scholar
• Xu X, Liu Y, Weiss S, et al. Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. Nucleic Acids Res 2003;31(24):7117-30
   PubMed Web of Science ®Google Scholar
• Cheng A, Zhang W, Xie Y, et al. Expression, purification, and characterization of SARS coronavirus RNA polymerase. Virology 2005;335(2):165-76
   PubMed Web of Science ®Google Scholar
• Zhai Y, Sun F, Li X, et al. Insights into SARS-CoV transcription and replication from the structure of the nsp7-nsp8 hexadecamer. Nat Struct Mol Biol 2005;12(11):980-6
   PubMed Web of Science ®Google Scholar
• Barnard DL, Hubbard VD, Burton J, et al. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine. Antivir Chem Chemother 2004;15(1):15-22
   PubMedGoogle Scholar
• Parker WB. Metabolism and antiviral activity of ribavirin. Virus Res 2005;107(2):165-71
   PubMed Web of Science ®Google Scholar
• Thomas HC, Torok ME, Forton DM, Taylor-Robinson SD. Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C. J Hepatol 1999;31(Suppl 1):152-9
   PubMed Web of Science ®Google Scholar
• Tan EL, Ooi EE, Lin CY, et al. Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis 2004;10(4):581-6
   PubMed Web of Science ®Google Scholar
• Avendano M, Derkach P, Swan S. Clinical course and management of SARS in health care workers in Toronto: a case series. Cmaj 2003;168(13):1649-60
   PubMed Web of Science ®Google Scholar
• Van Vonderen MG, Bos JC, Prins JM, et al. Ribavirin in the treatment of severe acute respiratory syndrome (SARS). Neth J Med 2003;61(7):238-41
   PubMedGoogle Scholar
• Barnard DL, Day CW, Bailey K, et al. Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. Antiviral Res 2006
   Google Scholar
• Barnard D, Day C, Wandersee M, et al. Evaluation of Interferon Inducers, Ribavirin and Mouse Hyperimmune Serum in a Pathogenesis/Lethal Mouse Model Using a Mouse-adapted SARS-CoV. Antiviral Res 2008;78(2):A20-A
   Google Scholar
• Knowles SR, Phillips EJ, Dresser L, Matukas L. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin Infect Dis 2003;37(8):1139-42
   PubMed Web of Science ®Google Scholar
• Olsen DB, Tomassini JE, Mao SS, et al., inventors; Inhibiting coronaviridae viral replication and treating coronaviridae viral infection with nucleoside compounds. Patent US20040259934; 2004
   Google Scholar
• Wilson L, Mc Kinlay C, Gage P, Ewart G. SARS coronavirus E protein forms cation-selective ion channels. Virology 2004;330(1):322-31
   PubMed Web of Science ®Google Scholar
• Wilson L, Gage P, Ewart G. Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication. Virology 2006;353(2):294-306
   PubMed Web of Science ®Google Scholar
• Ewart GD, Mills K, Cox GB, Gage PW. Amiloride derivatives block ion channel activity and enhancement of virus-like particle budding caused by HIV-1 protein Vpu. Eur Biophys J 2002;31(1):26-35
   PubMedGoogle Scholar
• Premkumar A, Wilson L, Ewart GD, Gage PW. Cation-selective ion channels formed by p7 of hepatitis C virus are blocked by hexamethylene amiloride. FEBS Lett 2004;557(1-3):99-103
   PubMed Web of Science ®Google Scholar
• Gage PW, Ewart GD, Wilson LE, et al., inventors; Antiviral compounds and methods. Patent US20070099968; 2007
   Google Scholar
• Plasterk RHA. RNA Silencing: The Genome's Immune System. Science (New York, NY ) 2002;296(5571):1263-5
   PubMed Web of Science ®Google Scholar
• Lu A, Zhang H, Zhang X, et al. Attenuation of SARS coronavirus by a short hairpin RNA expression plasmid targeting RNA-dependent RNA polymerase. Virology 2004;324(1):84-9
   PubMed Web of Science ®Google Scholar
• Shi Y, Yang DH, Xiong J, et al. Inhibition of genes expression of SARS coronavirus by synthetic small interfering RNAs. Cell Res 2005;15(3):193-200
   PubMedGoogle Scholar
• Tao P, Zhang J, Tang N, et al. Potent and specific inhibition of SARS-CoV antigen expression by RNA interference. Chin Med J 2005;118(9):714-9
   PubMedGoogle Scholar
• Wu CJ, Huang HW, Liu CY, et al. Inhibition of SARS-CoV replication by siRNA. Antiviral Res 2005;65(1):45-8
   PubMed Web of Science ®Google Scholar
• Zhang Y, Li T, Fu L, et al. Silencing SARS-CoV Spike protein expression in cultured cells by RNA interference. FEBS Lett 2004;560(1-3):141-6
   PubMed Web of Science ®Google Scholar
• Novina CD, Murray MF, Dykxhoorn DM, et al. siRNA-directed inhibition of HIV-1 infection. Nat Med 2002;8(7):681-6
   PubMed Web of Science ®Google Scholar
• Wilson JA, Jayasena S, Khvorova A, et al. RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc Natl Acad Sci USA 2003;100(5):2783-8
   PubMed Web of Science ®Google Scholar
• De Vincenzo J, Cehelsky JE, Alvarez R, et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res 2008;77(3):225-31
   PubMedGoogle Scholar
• Schiffelers RM, van Kolfschoten SC, van Dijk M, et al. siRNA as a new drug: intellectual property. Expert Opin Ther Patents 2005;15(2):141-52
   Web of Science ®Google Scholar
• He ML, Zheng B, Peng Y, et al. Inhibition of SARS-associated coronavirus infection and replication by RNA interference. Jama 2003;290(20):2665-6
   PubMed Web of Science ®Google Scholar
• Kung HF, He ML, Zheng BJ, et al., inventors; The University of Hong Kong, assignee. Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference. Patent US7129223; 2006
   Google Scholar
• Tang QT, Lu PY, Xie FY, et al., inventors; Intradigm Corporation, Rockville, MD, assignee. RNAi agents for anti-SARS coronavirus therapy. Patent US20070203082; 2007
   Google Scholar
• Li BJ, Tang Q, Cheng D, et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat med 2005;11(9):944-51
   PubMed Web of Science ®Google Scholar
• McSwiggen J, Chowrira B, Haeberli P, inventors; SIRNA Therapeutics, Inc., Boulder, CO (US), assignee. RNA interference mediated inhibition of severe acute respiratory syndrome (SARS) gene expression using short interfering nucleic acid. Patent US20070270360; 2007
   Google Scholar
• Sheehan D, Lunstad B, Yamada CM, et al. Biochemical properties of phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides. Nucleic Acids Res 2003;31(14):4109-18
   PubMed Web of Science ®Google Scholar
• Crooke ST, Ecker DJ, Rangarajan S, et al., inventors; Isis Pharmaceuticals, Inc., Carlsbad, CA (US), assignee. Compositions and methods for the treatment of severe acute respiratory syndrome (SARS). Patent US7339051; 2008
   Google Scholar
• Stein DA, Beswick RK, Iversen PL, et al., inventors; AVI BioPharma, Inc., assignee. Oligonucleotide compound and method for treating nidovirus infections. Patent US20070037763; 2007
   Google Scholar
• Li T, Zhang Y, Fu L, et al. siRNA targeting the leader sequence of SARS-CoV inhibits virus replication. Gene Ther 2005;12(9):751-61
   PubMed Web of Science ®Google Scholar
• Randall RE, Goodbourn S. Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. J Gen Virol 2008;89(Pt 1):1-47
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124(4):783-801
   PubMed Web of Science ®Google Scholar
• Kopecky-Bromberg SA, Martinez-Sobrido L, Frieman M, et al. Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol 2007;81(2):548-57
   PubMed Web of Science ®Google Scholar
• Frieman M, Yount B, Heise M, et al. Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J Virol 2007;81(18):9812-24
   PubMed Web of Science ®Google Scholar
• Wathelet MG, Orr M, Frieman MB, Baric RS. Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J Virol 2007;81(21):11620-33
   PubMed Web of Science ®Google Scholar
• Narayanan K, Huang C, Lokugamage K, et al. Severe Acute Respiratory Syndrome Coronavirus Nsp1 Suppresses Host Gene Expression, Including Type I Interferon, in Infected Cells. J Virol 2008
   PubMedGoogle Scholar
• Cinatl J, Morgenstern B, Bauer G, et al. Treatment of SARS with human interferons. Lancet 2003;362(9380):293-4
   PubMed Web of Science ®Google Scholar
• Gao ZC, Zhu JH, Sun Y, et al. Clinical investigation of outbreak of nosocomial severe acute respiratory syndrome. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2003;15(6):332-5
   PubMedGoogle Scholar
• Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. Jama 2003;290(24):3222-8
   PubMed Web of Science ®Google Scholar
• Wu W, Wang J, Liu P, et al. A hospital outbreak of severe acute respiratory syndrome in Guangzhou, China. Chin Med J (Engl) 2003;116(6):811-8
   PubMedGoogle Scholar
• Zhao Z, Zhang F, Xu M, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003;52(Pt 8):715-20
   PubMed Web of Science ®Google Scholar
• Zheng B, He ML, Wong KL, et al. Potent inhibition of SARS-associated coronavirus (SCOV) infection and replication by type I interferons (IFN-alpha/beta) but not by type II interferon (IFN-gamma). J Interferon Cytokine Res 2004;24(7):388-90
   PubMed Web of Science ®Google Scholar
• Hensley LE, Fritz LE, Jahrling PB, et al. Interferon-beta 1a and SARS coronavirus replication. Emerg Infect Dis 2004;10(2):317-9
   PubMed Web of Science ®Google Scholar
• Dahl H, Linde A, Strannegard O. In vitro inhibition of SARS virus replication by human interferons. Scand J Infect Dis 2004;36(11-12):829-31
   PubMedGoogle Scholar
• Paragas J, Blatt LM, Hartmann C, et al. Interferon alfacon1 is an inhibitor of SARS-corona virus in cell-based models. Antiviral Res 2005;66(2-3):99-102
   PubMedGoogle Scholar
• Stroher U, Di Caro A, Li Y, et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-alpha. J Infect Dis 2004;189(7):1164-7
   PubMed Web of Science ®Google Scholar
• Kumaki Y, Day CW, Wandersee MK, et al. Interferon alfacon 1 inhibits SARS-CoV infection in human bronchial epithelial Calu-3 cells. Biochem Biophys Res Commun 2008;371(1):110-3
   PubMed Web of Science ®Google Scholar
• Carter WA, Strayer D, inventors; Hemispherx Biopharma, Philadelphia, PA, assignee. Treating severe and acute viral infections. Patent US20060035859; 2006
   Google Scholar
• Carter WA, Strayer D, inventors; Hemispherx Biopharma, Philadelphia, PA, assignee. Treating severe acute respiratory syndrome. Patent US20070141080; 2007
   Google Scholar
• Tan ELC, Stanton LW, inventors; Inhibition of SARS coronavirus infection with clinically approved antiviral drugs. Patent US20060153803; 2006
   Google Scholar
• Haagmans BL, Kuiken T, Martina BE, et al. Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques. Nat Med 2004;10(3):290-3
   PubMed Web of Science ®Google Scholar
• Sainz B, Jr, Mossel EC, Peters CJ, Garry RF. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Virology 2004;329(1):11-17
   PubMed Web of Science ®Google Scholar
• Scagnolari C, Trombetti S, Alberelli A, et al. The synergistic interaction of interferon types I and II leads to marked reduction in severe acute respiratory syndrome-associated coronavirus replication and increase in the expression of mRNAs for interferon-induced proteins. Intervirology 2007;50(2):156-60
   PubMedGoogle Scholar
• Scagnolari C, Vicenzi E, Bellomi F, et al. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. Antivir Ther 2004;9(6):1003-11
   PubMed Web of Science ®Google Scholar
• Blatt LM, inventor Compositions and methods for treating coronavirus infection and SARS. Patent US20050002901; 2005
   Google Scholar
• Cinatl J, Jr, Michaelis M, Scholz M, Doerr HW. Role of interferons in the treatment of severe acute respiratory syndrome. Expert Opin Biol Ther 2004;4(6):827-36
   PubMedGoogle Scholar
• De Clercq E. Potential antivirals and antiviral strategies against SARS coronavirus infections. Expert Rev Anti Infect Ther 2006;4(2):291-302
   PubMedGoogle Scholar
• Haagmans BL, Osterhaus AD. Coronaviruses and their therapy. Antiviral Res 2006;71(2-3):397-403
   PubMed Web of Science ®Google Scholar
• Krieg AM, Yi AK, Matson S, et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995;374(6522):546-9
   PubMed Web of Science ®Google Scholar
• Takeshita F, Leifer CA, Gursel I, et al. Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 2001;167(7):3555-8
   PubMed Web of Science ®Google Scholar
• Yu Y, Wang L, inventors; Artificial CPG single-stranded oligodeoxynucleotide and antiviral use thereof. Patent US20070155683; 2007
   Google Scholar
• Bao M, Zhang Y, Wan M, et al. Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide. Clin Immunol 2005;118(2-3):180-7
   PubMedGoogle Scholar
• De Clercq E. Interferon: ten stories in one. A short review of some of the highlights in the history of an almost quinquagenarian. Acta Microbiol Immunol Hung 2005;52(3-4):273-89
   PubMedGoogle Scholar
• Padalko E, Nuyens D, De Palma A, et al. The Interferon Inducer Ampligen [Poly(I)-Poly(C12U)] Markedly Protects Mice against Coxsackie B3 Virus-Induced Myocarditis. Antimicrob Agents Chemother 2004;48(1):267-74
   PubMed Web of Science ®Google Scholar
• Leyssen P, Drosten C, Paning M, et al. Interferons, interferon inducers, and interferon-ribavirin in treatment of flavivirus-induced encephalitis in mice. Antimicrob Agents Chemother 2003;47(2):777-82
   PubMed Web of Science ®Google Scholar
• Gowen BB, Barnard DL, Smee DF, et al. Interferon alfacon-1 protects hamsters from lethal pichinde virus infection. Antimicrob Agents Chemother 2005;49(6):2378-86
   PubMed Web of Science ®Google Scholar
• Essey RJ, McDougall BR, Robinson WE Jr. Mismatched double-stranded RNA (polyI-polyC12;U) is synergistic with multiple anti-HIV drugs and is active against drug-sensitive and drug-resistant HIV-1 in vitro Antiviral Res 2001;51(3):189-202
   PubMedGoogle Scholar
• Thompson KA, Strayer DR, Salvato PD, et al. Results of a double-blind placebo-controlled study of the double-stranded RNA drug polyI:polyC12U in the treatment of HIV infection. Eur J Clin Microbiol Infect Dis 1996;15(7):580-7
   PubMed Web of Science ®Google Scholar
• Yuen KY, Chen F, Chan KH, et al., inventors; Baicalin and its derivatives as a treatment for SARS coronavirus infection or other related infections. Patent US20050215494; 2005
   Google Scholar
• Fleming RA, Hes JV, Huang Y, et al., inventors; Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses. Patent US20050187192; 2005
   Google Scholar
• Fiebach NH, Viscoli CM. Patient acceptance of influenza vaccination. Am J Med 1991;91(4):393-400
   PubMed Web of Science ®Google Scholar
• Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005;23(6):709-17
   PubMed Web of Science ®Google Scholar
• Tong TR. SARS coronavirus anti-infectives. Recent Patents Anti Infect Drug Discov 2006;1(3):297-308
   PubMedGoogle Scholar